The tablet, which is administered by placing it
under the tongue, is to treat the short ragweed pollen induced
allergic rhinitis. (http://r.reuters.com/nyg68v)
The approval for Ragwitek comes days after U.S. regulatory approval
for Merck's grass pollen allergy drug Grastek.
Merck's Grastek will compete with Stallergenes SA's immunotherapy
treatment for five types of grass pollen, which was approved by the
FDA earlier this month.
(Reporting by Shailesh Kuber; editing by Sriraj Kalluvila)
[© 2014 Thomson Reuters. All rights
2014 Reuters. All rights reserved. This material may not be
published, broadcast, rewritten or redistributed.